SCHEMBL29759586

SCHEMBL29759586

Cc1ncc(NC(=O)CN2CC(C)(C)C2)cc1NC(=O)c1cnn2cc(-c3cnn4c3COCC4)sc12

nearest known ligand 0.33

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ IRAK4 Q9NWZ3 8/20 0.33
▸ CCNT1 O60563 1/20 0.33
▸ CDK9 P50750 1/20 0.33
▸ WNT3A P56704 2/20 0.32
▸ WNT1 P04628 4/20 0.31
▸ GSK3B P49841 4/20 0.31
▸ DYRK1A Q13627 4/20 0.31
▸ RAF1 P04049 1/20 0.31
▸ BRAF P15056 1/20 0.31
▸ CHRM1 P11229 1/20 0.31
▸ PDGFRA P16234 1/20 0.31
▸ HRH3 Q9Y5N1 1/20 0.31
▸ F2 P00734 1/20 0.30
▸ F10 P00742 1/20 0.30
▸ IKBKE Q14164 1/20 0.30
▸ TBK1 Q9UHD2 1/20 0.30
▸ POLQ O75417 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24577467 1.00 IRAK4 (0.33) IRAK4CCNT1CDK9WNT3AWNT1
SCHEMBL24577464 0.93 WNT3A (0.34) IRAK4CCNT1CDK9WNT3AWNT1
SCHEMBL24578250 0.92 WNT3A (0.34) IRAK4CCNT1CDK9WNT3AWNT1
SCHEMBL24577950 0.91 WNT3A (0.32) IRAK4CCNT1CDK9WNT3AWNT1
SCHEMBL29759805 0.91 WNT3A (0.32) IRAK4CCNT1CDK9WNT3AWNT1
SCHEMBL30566527 0.90 POLQ (0.37) IRAK4CCNT1CDK9WNT1GSK3B
SCHEMBL27185047 0.90 POLQ (0.37) IRAK4CCNT1CDK9WNT1GSK3B
SCHEMBL29759708 0.89 CCNT1 (0.35) IRAK4CCNT1CDK9RAF1BRAF
SCHEMBL24579079 0.89 CCNT1 (0.35) IRAK4CCNT1CDK9RAF1BRAF
SCHEMBL24577425 0.89 CHRM1 (0.40) IRAK4CCNT1CDK9RAF1BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240109917-A1 PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS ACTELION PHARMACEUTICALS LTD (CH) 2024-04-04 — — US disclosed
EP-4267585-A1 PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS Actelion Pharmaceuticals Ltd (CH) 2023-11-01 — — EP disclosed
CN-116802184-A Pyrazolothiazole carboxamides and their use as PDGFR inhibitors 埃科特莱茵药品有限公司 2023-09-22 — — CN disclosed
WO-2022136509-A1 PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS ACTELION PHARMACEUTICALS LTD (CH) 2022-06-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109917-A1 PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS PDGFRA, PDGFRB, ABL1 IRAK4 1838/4885CCNT1 1550/4885CDK9 269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback